Cancer Res January 1 2017 77 (1) 1-2;
Ultrasound and nanodroplets stimulate release of extracellular vesicles from solid tumors, which enter the blood, suggesting that biomarkers from localized solid tumors can be analyzed from blood samples.
This study reveals a moonlighting function for the beta subunit of hemoglobin in blocking tumor growth and metastatic progression, possibly offering a biologic agent to prevent and treat cancer metastases.
Dietary emulsifier consumption perturbs host-microbiota interactions, leading to low-grade inflammation that favors colon carcinogenesis.
Newfound interactions between tumors and supporting stroma provide a rationale for simultaneous inhibition of multiple stromal signaling pathways in PDAC therapy.
Ca2+ signaling is suppressed in tumor-infiltrating lymphocytes in head and neck cancer patients and is associated with loss of effector functions in CD8+ T cells.
A new molecular actor links DNA methylation as an epigenetic mark to the maintenance of genomic stability and cancer prevention.
Simultaneous inhibition of HER2 and EGFR exploits their distinct roles supporting metastatic progression in human prostate cancer, given preclinical evidence of the efficacy of combination treatment.
These findings offer preclinical proof of concept for a strategy of dual targeting of the EGFR and PYK2/FAK kinases to treat triple-negative breast cancers with high EGFR levels, with near term clinical implications.
These results establish a pivotal mechanism of metastasis in KRAS-driven pancreatic cancers and suggest miR-489 as a candidate therapeutic target to address this disease.
These findings offer preclinical proof of concept for a cytotoxic nanotherapy to improve outcomes in rectal cancer patients receiving neoadjuvant chemoradiotherapy, in support of ongoing clinical evaluation of this nanotherapy.
Unexpected effects of deregulated PI3K signaling on neural progenitor cells identify alternative cells of origin for medulloblastoma, possibly underlying the heterogeneity found within the sonic hedgehog subgroup of this brain tumor.
Despite provocative earlier findings, this study finds no evidence that circulating hCG concentrations in early pregnancy act as a risk factor in mothers for later breast cancer risk.
A phospholipase that functions as a nodal modifier of colon cancer susceptibility mediates the cross-talk between two major tumor suppressor and oncogenic pathways, with implications for disease-selective therapeutic targeting.
In silico analysis of a transcriptional fingerprint assay reveals LKB1 loss to accurately predict sensitivity of tumors to MEK inhibitors.
This study defines a lipid metabolic enzyme as a critical driver of JAK2-mutant forms of an untreatable myeloproliferative disease, with implications to improve its therapeutic management.
These findings offer preclinical proof of concept for therapeutic use of a small-molecule inhibitor of the oncogenic kinase BRK in breast cancer.
Results suggest a therapeutic target and a cell surface biomarker to select lung adenocarcinoma patients who might benefit from treatment with a clinically approved SET inhibitor.
Recently developed multiplex DNA repair assays combine with mathematical modeling to provide a strategy for predicting the effectiveness of cancer therapy in individual patients.
This study illuminates the molecular pathobiology underlying extremely aggressive cases of adult acute myeloid leukemia, which associated with monosomy of chromosome 7, with possible implications to improve its treatment.